You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

INCS provides better nasal symptom control and quality of life outcomes compared to OAH 1

Efficacy vs antihistamines woman and man

The same results were first published in Juel-Berg N, et al. Am J Rhinol Allergy 2017;31(1):19–28. The figure has been independently created by GSK from the original data.

A meta-analysis showed INCS provides better nasal symptom control and QoL outcomes compared to OAH. 1

AR: allergic rhinitis; INCS: intranasal corticosteroid; OAH: oral antihistamine.

References

  1. Juel-Berg N, Darling P, Bolvig J, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy 2017;31(1):19–28.

Avamys is a registered trademark of the GlaxoSmithKline group of companies